App-Quantinova.ai

Phase 1 study of CB-839, a small molecule inhibitor of glutaminase (GLS) in combination with paclitaxel (Pac) in patients (pts) with triple negative breast cancer (TNBC).

Angela DeMichele - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Paclitaxel

Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.

Priyanka Sharma - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Triple-negative breast cancer

Carboplatin

Genome wide association study for anthracycline-induced congestive heart failure.

Laura Gardner - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Congestive heart failure

N/A

The role of post-mastectomy radiotherapy among 3,437 women with pathologic T3N0M0 breast cancer in the national cancer data base.

Richard John Cassidy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A multi-marker prognostic to assess risk of invasive recurrence in DCIS patients.

Troy Bremer - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

N/A

The association of surgical margins and local recurrence in women with ductal carcinoma in situ treated with breast-conserving therapy: A meta-analysis.

Michael Luke Marinovich - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Skeletal muscle area and density as predictors of chemotherapy toxicity and outcomes in metastatic breast cancer.

Shlomit Strulov Shachar - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Effect of chemotherapy on survival in T1c T2N0M0 medullary breast cancer: 3,976 cases from the National Cancer Data Base.

Alina M. Mateo - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Accrual of older patients (pts) with breast cancer to Alliance systemic therapy trials over time: A151527.

Rachel A. Freedman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Lymphovascular invasion and survival in breast cancer after neoadjuvant chemotherapy.

Ying Liu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Adriamycin injection

Association of Charcot-Marie-Tooth gene, SBF2, with taxane-induced peripheral neuropathy in African Americans.

Bryan P. Schneider - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Peripheral neuropathy

Paclitaxel

A model for trial level prediction of long term outcome based on pathological complete response (pCR) after neoadjuvant chemotherapy for early-stage breast cancer (EBC).

Valentina Nekljudova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Predictive value of topoisomerase 1 by immunohistochemistry (TOP1 IHC) in patients with metastatic breast cancer receiving irinotecan-based therapy.

Nicholas J. Robert - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

Fluorouracil

Impact of delayed neoadjuvant systemic chemotherapy on survival outcomes in breast cancer patients.

Rachel Ann Sanford - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

The changing utilization of neoadjuvant chemotherapy among different racial groups and its effect on mastectomy rates.

Tiffany Pinchinat - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Can radiation therapy adequately address positive surgical margins in elderly women (70 years) with stage I ER+ breast cancer?

Kaelen Medeiros - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

A model to predict axillary nodal pathologic complete response following neoadjuvant chemotherapy for breast cancer.

Olga Kantor - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Management of lobular carcinoma in situ: A decision analysis.

Stephanie M Wong - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Effect of elevated BMI on radiation toxicity in early stage breast cancer patients.

Jordan Silberg - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Beyond the margins: Economic costs and complication rates associated with repeated breast-conserving surgeries.

Leanne N. Metcalfe - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Breast cancer

N/A

Filters

255783 Abstracts